Early-stage trial of endothelin antagonist yields enhancements in diabetic retinopathy
July 01, 2025
2 min watch
LAS VEGAS — On this Healio Video Perspective from Medical Trials on the Summit, Arshad M. Khanani, MD, MA, FASRS, highlights first-time outcomes of PER-001 intravitreal implant in diabetic retinopathy.
PER-001 (Perfuse Therapeutics), an endothelin antagonist, was delivered at high and low doses and in contrast with management, displaying construction enhancements in macular ischemia, leakage and microaneurysms. Moreover, in a glaucoma program, sufferers skilled improved OCT retinal nerve fiber layer and blood circulation to the optic nerve.
“When it comes to perform, we truly noticed enchancment in low-luminance distinction sensitivity in addition to visible acuity,” Khanani stated. “We noticed an enchancment in peripheral imaginative and prescient in these sufferers with diabetic retinopathy.”
The implant was nicely tolerated, with no reported security alerts.
Sources/Disclosures
Collapse
Khanani A. PER-001: A novel, long-acting endothelin antagonist IVT implant for the therapy of retinal
ischemia in glaucoma, DR, and AMD. Introduced at: Medical Trials on the Summit; June 21, 2025; Las Vegas.
Disclosures:
Healio couldn’t verify related monetary disclosures on the time of publication.
